(Q35099083)

6 August 2017

1 reference

title

Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

Pi-Lin Sung

1

1 reference

6 August 2017

Yen-Hou Chang

2

1 reference

6 August 2017

Kuan-Chong Chao

3

1 reference

6 August 2017

Chi-Mu Chuang

4

1 reference

6 August 2017

Task Force on Systematic Review and Meta-analysis of Ovarian Cancer

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

17 February 2014

1 reference

6 August 2017

1 reference

6 August 2017

volume

133

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

147-154

1 reference

6 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

7 January 2021

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

My approach to and thoughts on the typing of ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian cancer histology-specific incidence trends in Canada 1969-1993: age-period-cohort analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian cancer incidence in the United States, 1992-1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Is hysterectomy needed in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian cancer incidence and survival in Korea: 1993-2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

PIK3CA mutations in advanced ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Population attributable fractions for ovarian cancer in Swedish women by morphological type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Second neoplasms after invasive and borderline ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Ovarian cancer and hormone replacement therapy in the Million Women Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Body size and risk of epithelial ovarian and related cancers: a population-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Assessment of regional treatment effect in a multiregional clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Endometriosis-associated ovarian cancer: a review of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.02.016

10.1016/J.YGYNO.2014.02.016

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference